ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 164 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $118,083,000 | +13.1% | 1,679,460 | +14.2% | 0.02% | +4.8% |
| Q3 2016 | $104,365,000 | +53.4% | 1,471,171 | +5.8% | 0.02% | +40.0% |
| Q2 2016 | $68,033,000 | -25.5% | 1,390,985 | -3.6% | 0.02% | -28.6% |
| Q1 2016 | $91,347,000 | -42.6% | 1,442,851 | +1.6% | 0.02% | -43.2% |
| Q4 2015 | $159,235,000 | +11.5% | 1,419,462 | -4.3% | 0.04% | 0.0% |
| Q3 2015 | $142,864,000 | +6.0% | 1,483,381 | +12.7% | 0.04% | +15.6% |
| Q2 2015 | $134,793,000 | +241.8% | 1,316,464 | +107.3% | 0.03% | +255.6% |
| Q1 2015 | $39,431,000 | +62.8% | 635,055 | +15.1% | 0.01% | +50.0% |
| Q4 2014 | $24,219,000 | +183.2% | 551,945 | +265.3% | 0.01% | +200.0% |
| Q3 2014 | $8,553,000 | +29.1% | 151,106 | +2.4% | 0.00% | 0.0% |
| Q2 2014 | $6,624,000 | -17.7% | 147,569 | -10.4% | 0.00% | 0.0% |
| Q1 2014 | $8,049,000 | – | 164,642 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |